Most importantly, novel therapies for renal cancer have been developed targeting the VHL-HIF pathway; thus, broad profiling of VHL aberrations may open the possibility to administer these drugs to a wide range of patients [43–45]. This evidence concerns the gene VHL and renal carcinoma.